-
Antiviral API
- Arenavirus
- Cytomegalovirus (CMV)
- Dengue virus
- Endogenous Metabolite
- Enterovirus (EV)
- Epstein-Barr virus (EBV)
- Filovirus
- Flavivirus
- HCV Protease
- Hepatitis B Virus (HBV)
- Hepatitis C Virus (HCV)
- Herpes simplex Virus (HSV)
- HIF/HIF Prolyl-Hydroxylase
- HIV Integrase
- HIV Protease
- Human immunodeficiency Virus (HIV)
- Human papillomavirus (HPV)
- Influenza Virus
- Nipah virus
- Orthopoxvirus
- Others
- Rabies virus (RABV)
- Respiratory syncytial Virus (RSV)
- Reverse Transcriptases (RTs)
- SARS-CoV
- Tobacco mosaic virus (TMV)
- Vesicular stomatitis virus (VSV)
- Virus Protease
- West Nile virus
- Antiviral intermediates
Fozivudine tidoxil
![{PARAM:[Name]}()](https://resource.bocsci.com/structure/141790-23-0.gif)
| Category | Human immunodeficiency Virus (HIV) |
| CAS | 141790-23-0 |
| Description | Fozivudine tidoxil, an orally active thioether lipid-zidovudine (ZDV) conjugate with anti-HIV activity, is a reverse transcriptase inhibitor potentially for the treatment of HIV infection. Fozivudine tidoxil, a member of the NRTI family, is incorporated into the newly synthesized DNA strand during intracellular viral replication and irreversibly binds to the viral RT, thereby disrupting the reverse transcription of the virus. |
Product Information
| Synonyms | BM-211290; Fozivudine; 3'-Azido-3'-deoxy-5'-thymidylic Acid Mono(2-(decyloxy)-3-(dodecylthio)propyl) Ester; 3'-Azido-5'-O-{[2-(decyloxy)-3-(dodecylsulfanyl)propoxy](hydroxy)phosphoryl}-3'-deoxythymidine; 5'-Thymidylic acid, 3'-azido-3'-deoxy-, mono(2-(decyloxy)-3-(dodecylthio)propyl) ester |
| IUPAC Name | [(2S,3S,5R)-3-azido-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methyl (2-decoxy-3-dodecylsulfanylpropyl) hydrogen phosphate |
| Molecular Weight | 745.95 |
| Molecular Formula | C35H64N5O8PS |
| Canonical SMILES | CCCCCCCCCCCCSCC(COP(=O)(O)OCC1C(CC(O1)N2C=C(C(=O)NC2=O)C)N=[N+]=[N-])OCCCCCCCCCC |
| InChI | InChI=1S/C35H64N5O8PS/c1-4-6-8-10-12-14-15-17-19-21-23-50-28-30(45-22-20-18-16-13-11-9-7-5-2)26-46-49(43,44)47-27-32-31(38-39-36)24-33(48-32)40-25-29(3)34(41)37-35(40)42/h25,30-33H,4-24,26-28H2,1-3H3,(H,43,44)(H,37,41,42)/t30?,31-,32+,33+/m0/s1 |
| InChIKey | IBHARWXWOCPXCR-WELGVCPWSA-N |
| Purity | ≥95% |
| Solubility | Soluble in DMSO |
| Appearance | Solid Powder |
| Storage | Store at 2-8°C for short term (days to weeks) or -20°C for long term (months to years) |
| Complexity | 1100 |
| Exact Mass | 745.42132219 |
| In Vitro | Fozivudine tidoxil (BM-211290) is a member of the nucleoside analogue reverse transcriptase inhibitor (NRTI) family. |
| In Vivo | Fozivudine tidoxil (BM-211290; 45 mg/kg; PO; twice daily; one day before FIV challenge for a total of six weeks) is effective at lowering plasma- and cell-associated viremia at two weeks post-FIV infection. Result: Effective at lowering plasma- and cell-associated viremia at two weeks post-feline immunodeficiency virus (FIV) infection with a trend toward lower plasma- and cell- associated viremia at four and six weeks post-infection (PI). |
| PSA | 214.20000 |
| Target | HIV; DNA/RNA Synthesis |
| XLogP3-AA | 10.1 |
